ASCO 2026

Summaries from 2026 ASCO Annual Meeting, held from May 29 – June 2, 2026.

Adjuvant selpercatinib improves event-free survival in RET fusion-positive non-small cell lung cancer, LIBRETTO-432 trial shows

Presenter: Jonathan W. Goldman, MD, University of California, Los Angeles, Los Angeles, CA

Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial. Abstract LBA3. Presented at the 2026 ASCO Annual Meeting, Chicago, IL.

Daraxonrasib doubles survival in previously treated metastatic pancreatic cancer, phase 3 data show

Presenter: Brian M. Wolpin, MD, MPH, Dana-Farber Cancer Institute, Boston, MA

Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. Abstract LBA5. Presented May 31, 2026.

Neoadjuvant recurrence scores redirect treatment decisions in early HR-positive, HER2-negative breast cancer, prospective study shows

Presenter: Natasha Caminsky, Université de Montréal, Montréal, QC, Canada

Application of a neoadjuvant 21-gene breast recurrence score assay to redirect surgical and systemic treatment pathways in early breast cancer: a multicenter prospective study. Abstract 596. Presented at the 2026 ASCO Annual Meeting, Chicago, IL.

ctDNA-guided adjuvant chemotherapy may improve efficacy outcomes in stage II colon cancer, CIRCULATE analysis suggests

Presenter: Gunnar Folprecht, MD, Technical University Dresden, University Hospital Carl Gustav Carus, Dresden, Germany

Disease-free survival (DFS) and time to recurrence (TTR) with circulating tumor (ct)DNA-based decision for adjuvant treatment in colon cancer stage II (CIRCULATE): an AIO (KRK-0217)/ABCSG trial. Abstract LBA3500.

AI-based analysis provides independent prognostic value in early breast cancer, TAILORx validation study shows

Presenter: Johan Hartman, MD, PhD, Department of Oncology-Pathology, Karolinska Institutet, and Stratipath AB, Stockholm, Sweden

Prognostic validation of artificial intelligence (AI)-based Stratipath breast risk stratification in TAILORx. Abstract 555. Presented June 1, 2026.

Encorafenib and cetuximab plus FOLFIRI improves progression-free survival in BRAF V600E-mutant metastatic colorectal cancer, BREAKWATER analysis shows

Presenter: Scott Kopetz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). Abstract LBA3503. Presented May 31, 2026.

Abemaciclib significantly prolongs progression-free survival in advanced dedifferentiated liposarcoma, phase 3 SARC041 trial shows

Presenter: Mark A. Dickson, MD, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. Abstract LBA2. Presented May 31, 2026.

GLP-1 drugs linked to reduced progression to metastasis in multiple cancer types

Presenter: Mark D. Orland, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. Presented May 30, 2026.

Perioperative apalutamide plus androgen deprivation therapy improves oncologic outcomes in high-risk localized prostate cancer, PROTEUS phase 3 trial shows

Presenter: Mary-Ellen Taplin, MD, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study. Abstract LBA1. Presented May 31, 2026.